A Randomized Double-masked 14-day Study to Compare the Ocular Safety, Tolerability, and Efficacy of Differing Dosing Regimens of ISV-303 (0.075% Bromfenac in DuraSite [Rm]) to Vehicle and Xibrom [Rm] in Post Cataract Surgery Volunteers.

Trial Profile

A Randomized Double-masked 14-day Study to Compare the Ocular Safety, Tolerability, and Efficacy of Differing Dosing Regimens of ISV-303 (0.075% Bromfenac in DuraSite [Rm]) to Vehicle and Xibrom [Rm] in Post Cataract Surgery Volunteers.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 15 Jul 2016

At a glance

  • Drugs Bromfenac (Primary)
  • Indications Ocular inflammation; Ocular pain; Postoperative pain
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Mar 2011 NCT reports actual end date as (1 Jan 2011).
    • 21 Mar 2011 Secondary endpoint 'Patient-assessment-of-pain' has been met.
    • 21 Mar 2011 Primary endpoint "Absence of cells in the anterior chamber of the eye" has been met
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top